Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2019 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference

NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen...
February 20, 2019 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme

Phase 1 trial underway at the University of Alabama at Birmingham in recurrent glioblastoma multiforme Mustang intends to combine the oncolytic virus (C134) with MB-101 (IL13Rα2-specific CAR) to...
December 20, 2018 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

NEW YORK, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor...
November 28, 2018 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy

NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor...
November 13, 2018 16:20 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor...
October 30, 2018 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope

First-of-its-kind Phase 1 clinical trial using intraventricular delivery of CAR T cells to brains of patients with HER2-positive breast cancer with brain metastases now enrolling patients First...
October 15, 2018 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer

NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor...
October 01, 2018 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa

NEW YORK, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on...
September 04, 2018 07:15 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018

NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on...
August 30, 2018 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio to Participate in September Investor Conferences

NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on...